Most people who transition from semaglutide to tirzepatide have hit a wall of some kind, whether that wall involves stalled weight loss , persistent side effects, or simply wanting better results based on the clinical data now available
Semaglutide and tirzepatide both suppress appetite through related but distinct mechanisms, and neither one changes your body's underlying need for protein during weight loss
The needles are tiny, similar to insulin syringes, and most patients find injections quick and painless
In August this year, the Therapeutic Goods Administration (TGA) approved semaglutide (marketed as Ozempic) for reducing the risk of kidney disease progression in patients with type 2 diabetes and chronic kidney disease
In 2017, subcutaneous semaglutide was approved for once-weekly administration [23], becoming only the second approved once-weekly GLP-1RA (after dulaglutide)
But convenience does not always equal effectiveness